Publication about the AID2 technology as a collaboration with National Institute of Genetics
News release Download PDF
Kanagawa, Japan – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on protein degradation, today announces that the results of research collaboration with National Institute of Genetics has been published in Nature Communications, November 11, 2020.
Title: The auxin-inducible degron 2 technology provides sharp degradation control in yeast, mammalian cells, and mice.
Authors: A Yesbolatova, Y Saito, *N Kitamoto, H Makino-Itou, R Ajima, R Nakano, H Nakaoka, K Fukui, *K Gamo, *Y Tominari, H Takeuchi, Y Saga, K Hayashi, MT Kanemaki
(*Member in FIMECS)
In collaboration with Dr. Kanemaki, a professor at National Institute of Genetics, we focused on developing a novel target validation technology for drug discovery based on targeted protein degradation by utilizing an improved auxin-inducible degron (AID) technology called AID2 that works in vivo.
“We are delighted to publish promising results in collaboration with Professor Kanemaki and his group.
Applying their extensive experience and knowledge of the AID2 technology into our drug discovery will create a strong platform for validation of target proteins.” said Yusuke Tominari, Ph.D., Co-founder, CEO and CSO of FIMECS. “Combined with our proprietary degrader discovery platform “RaPPIDS™”, we can accelerate the generation of innovative drugs for undruggable proteins. We look forward to a productive relationship.”
For More Information: https://www.nig.ac.jp/nig/2020/11/research-highlights/pr20201111.html
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of targeted protein degradation therapeutics for the treatment of cancer patients. By integrating proprietary E3 ligase binder with molecule-designing capability, the company is developing proprietary therapeutic programs to rapidly induce the degradation of targeted proteins along with “RaPPIDS™” platform. Utilizing our drug discovery platform to internal and collaboration projects, the company seeks to provide life-saving medicine to patients all over the world.
About AID2 technology:
The technology enables the rapid and inducible degradation of AID-tagged target proteins in mammalian cells and mice by the addition of a small ligand that is an analog of the plant hormone auxin.
# # #
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan